Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 11/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084802 | 0.87 | PDE3B (0.77) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| SCHEMBL11398470 | 0.84 | PDE3B (0.73) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Hydrochloric Acid SCHEMBL11278036 | 0.83 | PDE3B (0.71) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| SCHEMBL8196489 | 0.82 | PDE3B (0.70) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| SCHEMBL4578707 | 0.76 | PDE3B (0.62) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| SCHEMBL13400001 | 0.75 | PDE3B (0.60) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL5060881 | 0.72 | PDE3B (1.00) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL9411 | 0.72 | PDE3B (1.00) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL29491059 | 0.72 | PDE3B (1.00) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| SCHEMBL11391653 | 0.72 | PDE3B (0.76) | PDE3BPDE3AMEN1PDE2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | claimed |
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | disclosed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | disclosed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | disclosed |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9750698-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750698-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1949893-A2 | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | Shire Holdings AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| EP-1949893-A2 | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | Shire Holdings AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-20060052601-A1 | Quinazoline derivatives and their use in the treatment of thrombocythemia | SHIRE HOLDINGS AG (CH) | 2006-03-09 | — | — | US | disclosed |
| US-20060030574-A1 | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | SHIRE HOLDINGS AG (CH) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | PF4, PLAT, VASP | PDE3B 64/4885PDE3A 50/4885MEN1 972/4885 |
| US-20060052601-A1 | Quinazoline derivatives and their use in the treatment of thrombocythemia | ABL1, MPL, PFKP | PDE3B 340/4885PDE3A 280/4885MEN1 551/4885 |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885MEN1 996/4885 |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | PDE3B 69/4885PDE3A 60/4885MEN1 996/4885 |
| US-20060030574-A1 | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | PDE3B 1/4885PDE3A 2/4885MEN1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.